Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes
The clinical course in patients with prostate cancer (PCa) after biochemical failure (BF) has received limited attention. This study analyzes survival time from recurrence, patterns of progression, and the efficacy of salvage therapies in patients treated with radical or postoperative radiotherapy (RT).
This is a multicenter retrospective comparative study of 1135 patients diagnosed with BF and treated with either radical (882) or postoperative (253) RT. Data correspond to the RECAP database. Clinical, tumor, and therapeutic characteristics were collected. Descriptive statistics, survival estimates, and comparisons of survival rates were calculated.
Time to BF from initial treatment (RT or surgery) was higher in irradiated patients (51 vs 37 months). At a median follow-up of 102 months (14–254), the 8-year cause-specific survival (CSS) was 80.5%, without significant differences between the radical (80.1%) and postoperative (83.4%) RT groups. The 8-year metastasis-free survival rate was 57%. 173 patients (15%) died of PCa and 29 (2.5%) of a second cancer. No salvage therapy was given in 15% of pts. Only 5.5% of pts who underwent radical RT had local salvage treatment and 71% received androgen deprivation (AD) ± chemotherapy. The worst outcomes were in patients who developed metastases after BF (302 pts; 26.5%) and in cases with a Gleason > 7.
In PCa treated with radiotherapy, median survival after BF is relatively long. In this sample, no differences in survival rates at 8-years have been found, regardless of the time of radiotherapy administered. AD was the most common treatment after BF. Metastases and high Gleason score are adverse variables. To our knowledge, this is the first study to compare outcomes after BF among patients treated with primary RT vs. those treated with postoperative RT and to evaluate recurrence patterns, treatments administered, and causes of death. The results allow avoiding overtreatment, improving quality of life, without negatively affecting survival.
KeywordsProstate cancer Biochemical failure Radiotherapy Survival rate Salvage therapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any experimental studies with human participants or animals performed by any of the authors. The clinical data review was approved by the Clinical Research Ethics Committees at each centre.
For this type of study formal consent is not required.
- 5.D’Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281–6.CrossRefGoogle Scholar
- 6.González-San Segundo C, Herranz F, Álvarez A, Cuesta P, Gómez M, Paños E, Santos JA. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control. In search of the optimal treatment. Ann Surg Oncol. 2011;18:2980–7. https://doi.org/10.1245/s10434-011-1660-0.CrossRefGoogle Scholar
- 7.Roach M, Hanks G, Thames H Jr, et al. Defining Biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.CrossRefGoogle Scholar
- 8.Cookson MS, Aus G, Burnett AL, Cinby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition el biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540–5.CrossRefGoogle Scholar
- 11.NCCN clinical practice guidelines in prostate cancer, Version 2.2017; 2017. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed Oct 2017.
- 18.Abdollah F, Boorjian SA, Cozzarini C, Suardi N, Sun M, Fiorino C, et al. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Cancer. 2013;64(4):557–64.Google Scholar
- 20.Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol. 2015;67:204–9.CrossRefGoogle Scholar
- 21.López Torrecilla J, Hervás A, Zapatero A, Gómez Caamaño A, Macías V, Herruzo I, et al. Uroncor consensus statement: management of biochemical recurrence after radiotherapy for prostate cancer: from biochemical failure to castration resistance. Rep Pract Oncol Radiot. 2015;20:259–72.CrossRefGoogle Scholar
- 25.Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, et al. Cancer-specific survival after metastasis following primary prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol. 2014;65:693–700.CrossRefGoogle Scholar
- 29.Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F] choline PET/TC in the detection of local prostate recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol. 2012;81:700–8.CrossRefGoogle Scholar
- 39.Prada PJ, Jiménez I, González-Suárez H, Fernández J, Cuervo-Arango C, Méndez L. High-dose-rate interstitial brachytherapy as monotherapy in one fraction and transperineal hyaluronic acid injection into the perirectal fat for the treatment of favorable stage prostate cancer: treatment description and preliminary results. Brachytherapy. 2012;11:105–10.CrossRefGoogle Scholar
- 41.Carrie C, Hasbini A, De Laroche G, Richaud P, Guerif S, Latorzeff I, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicentre, open-label phase 3. Lancet Oncol. 2016;17:747–56.CrossRefGoogle Scholar